Latest Breaking News On - கமடோர் மூலதனம் - Page 1 : comparemela.com

Published: May 03, 2021   SAN DIEGO, May 3, 2021 /PRNewswire/  Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of Vanessa L. Jacoby as Chief Financial Officer. Ms. Jacoby brings more than twenty years of experience as a financial leader to Shoreline, with a strong background in company building and financial strategy. I am pleased to welcome Vanessa to Shoreline as our Chief Financial Officer, said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder and Executive Chairman.   Vanessa s recent IPO and public markets experience, coupled with a proven track record in building and financing companies through critical phases of growth, will be invaluable to our team as we grow into a domain-do

State of californiaUnited statesSao pauloSan diegoNational universityKleanthisg xanthopoulosVanessal jacobyArmando alvares penteadoCell therapy laboratoryEbci incErnst youngBusiness administrationShoreline biosciences incAvidity biosciences incShoreline coShoreline biosciences